Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
91-105 of 4332 results
SillaJen initiates phase 1/2 trial of Pexa-Vec in metastatic colon cancer
SillaJen has initiated a phase 1/2 clinical trial of pexastimogene devacirepvec (Pexa-Vec) in combination with checkpoint inhibitor therapy for the treatment of metastatic colon cancer.
Contract Research & Services > Clinical Trials > News
AstraZeneca’s PT010 triple combination therapy shows significant effect in COPD trial
AstraZeneca has reported top-line results from the Phase III KRONOS trial, which showed significant effect of PT010 triple combination therapy in chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
Alligator appoints Theradex Oncology as clinical CRO for ATOR-1015 phase I study
Alligator Bioscience has appointed Theradex Oncology has appointed as CRO for the planned phase I study of ATOR-1015 for the treatment of metastatic cancer.
Contract Research & Services > Clinical Trials > News
Rexgenero starts phase III program with REX-001 for CLI treatment
By PBR Staff Writer
UK-based regenerative medicine company Rexgenero has treated first patient in its phase III program with lead product REX-001, a cell therapy for the treatment of Critical Limb Ischemia (CLI)
Contract Research & Services > Clinical Trials > News
Alzheimer’s drug Solanezumab fails to slow cognitive decline in clinical study
By PBR Staff Writer
A study has demonstrated that Alzheimer’s drug, solanezumab, targeting amyloid plaques, did not significantly slow cognitive decline.
Contract Research & Services > Clinical Trials > News
Pfizer’s rituximab biosimilar succeeds in phase III follicular lymphoma trial
By PBR Staff Writer
Pfizer’s PF-05280586, a potential biosimilar to rituximab, has met its primary endpoint of overall response rate in a clinical trial of patients with CD20-positive follicular lymphoma and low tumor burden.
Contract Research & Services > Clinical Trials > News
SymBio begins phase 1 trial for treakisym in progressive solid tumors
SymBio Pharmaceuticals has launched a phase 1 study in Japan for oral Treakisym in patients with progressive solid tumors.
Contract Research & Services > Clinical Trials > News
ImmuPharma completes phase 3 trial of Lupus drug
ImmuPharma has completed its 52-week, randomised, double-blinded, phase 3 clinical trial of Lupuzor, its lead candidate for the potential breakthrough compound for Lupus.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda regimen succeeds in phase 3 NSCLC trial
By PBR Staff Writer
Merck’s Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) plus platinum chemotherapy has significantly improved overall survival (OS) and progression-free survival (PFS) of certain type of lung cancer patients in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
Allergy Therapeutics completes patient recruitment in PQ Birch phase III clinical trial
Allergy Therapeutics has completed recruitment of patients in the PQ Birch phase III clinical trial.
Contract Research & Services > Clinical Trials > News
BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 in NSCLC
BerGenBio announced that it met the first efficacy endpoint in the phase II clinical trial evaluating BGB324 (bemcentinib), a selective AXL inhibitor, in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who have progressed on an approved EGFR inhibitor.
Contract Research & Services > Clinical Trials > News
Inovio, Parker Institute to jointly evaluate cancer immunotherapy combinations
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy have signed a clinical collaboration agreement to assess novel combination regimens within the field of immuno-oncology.
Contract Research & Services > Clinical Trials > News
Axovant scraps dementia drug development after negative results
By PBR Staff Writer
Axovant Sciences said it will no longer develop intepirdine, its lead candidate for dementia, after failing to meet several goals in recent studies.
Contract Research & Services > Clinical Trials > News
Momenta, Mylan to start trial of biosimilar to eye drug Eylea
By PBR Staff Writer
Momenta Pharmaceuticals and Mylan have unveiled plans to commence pivotal clinical study of a biosimilar to Regeneron’s eye drug Eylea (aflibercept).
Contract Research & Services > Clinical Trials > News
Centrexion secures funding to begin trial of knee osteoarthritis pain drug
By PBR Staff Writer
Centrexion Therapeutics has secured $67m funding to launch phase 3 progam of CNTX-4975 therapy for the treatment of chronic pain due to knee osteoarthritis (OA).
Contract Research & Services > Clinical Trials > News
91-105 of 4332 results